Journals 2023
Publications menu
A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinoma.
Carcinogenesis.
2023,
ISSN: 0143-3334,
PMID: 37670727,
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
Molecular Cancer Therapeutics.
2023,
22(12),
1390-1403,
ISSN: 1535-7163,
PMID: 37616542,
TET protein inhibitors: Potential and limitations.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie.
2023,
166,
115324,
ISSN: 0753-3322,
PMID: 37598475.
Circulating tumor cell-derived preclinical models: current status and future perspectives.
Cell Death & Disease.
2023,
14(8),
530,
ISSN: 2041-4889,
PMID: 37591867,
The adenylate cyclase toxin RTX domain follows a series templated folding mechanism with implications for toxin activity.
The Journal of Biological Chemistry.
2023,
299(9),
105150,
ISSN: 0021-9258,
PMID: 37567473,
A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis.
Science Translational Medicine.
2023,
15(708),
eabn7491,
ISSN: 1946-6234,
PMID: 37556558,
Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors.
Journal of Medicinal Chemistry.
2023,
66(14),
9577-9591,
ISSN: 0022-2623,
PMID: 37450644,